# Determining the Optimal Sequence of Multiple Tests

**Authors:** Lucas Böttcher, Stefan Felder

PMC · DOI: 10.1002/sim.70254 · Statistics in Medicine · 2025-10-17

## TL;DR

This paper introduces a method to determine the best sequence of medical tests by balancing diagnostic accuracy, treatment benefits, and testing costs.

## Contribution

The paper introduces a novel framework for quantifying incremental net benefit of tests and determining optimal test sequences.

## Key findings

- The optimal test sequence depends on disease probability and treatment cost-benefit trade-offs.
- An online tool visualizes incremental net benefit for combined tests.
- Examples in prostate, colorectal, and coronary diagnostics show test choices depend on multiple factors.

## Abstract

The use of multiple tests can improve medical decision making by balancing the benefits of correctly treating ill patients and avoiding unnecessary treatment for healthy individuals against the potential harms of missed diagnoses, inappropriate treatments, and the costs and risks associated with testing. We quantify the incremental net benefit (INB) of single and multiple tests by accounting for a patient's pre‐test probability of disease and the associated benefits, harms, and cost of treatment and testing. We decompose the INB into two components: one that captures the value of information provided by the test, independent of the cost and possible harm of testing, and another that accounts for test costs and harm. Next, we examine conjunctive, disjunctive, and majority aggregation functions, demonstrating their application through examples in prostate cancer, colorectal cancer, and stable coronary artery disease diagnostics. Our approach complements traditional threshold and decision‐curve analysis by varying both the pre‐test probability of disease and the cost‐benefit trade‐off of treatment to identify the region over which a given test provides the highest INB. Using empirical test and cost data, we compute decision boundaries to determine when conjunctive, disjunctive, majority, or even single tests are optimal, and, for combinations of tests, in what order they should be administered. In all three application examples, we find that the optimal choice and sequence of tests jointly depend on the probability of disease and the cost‐benefit trade‐off of treatment. An online tool that visualizes the INB for combined tests is available at 
https://optimal‐testing.streamlit.app/.

## Linked entities

- **Diseases:** prostate cancer (MONDO:0005159), colorectal cancer (MONDO:0005575)

## Full-text entities

- **Diseases:** prostate cancer (MESH:D011471), coronary artery disease (MESH:D003324), colorectal cancer (MESH:D015179)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12533563/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12533563/full.md

## References

44 references — full list in the complete paper: https://tomesphere.com/paper/PMC12533563/full.md

---
Source: https://tomesphere.com/paper/PMC12533563